支氣管擴(kuò)張癥(簡(jiǎn)稱支擴(kuò))是以進(jìn)行性和不可逆性氣道破壞和擴(kuò)張為特征的慢性氣道炎癥性疾病[1],大多表現(xiàn)為長(zhǎng)期咳嗽、咳膿性痰,反復(fù)急性發(fā)作,肺功能受損,后者主要表現(xiàn)為阻塞性通氣功能障礙,氣道反應(yīng)性增高,晚期患者常常出現(xiàn)勞力性呼吸困難,嚴(yán)重影響患者生活質(zhì)量[2,3] 。大部分支擴(kuò)患者第1秒用力呼氣容積(FEV )每年下降大約50mL [4] 。在我國(guó)支擴(kuò)的發(fā)病率為0.3‰~0.5‰。2005年美國(guó)成人支擴(kuò)發(fā)病率約為52.3/100 000。發(fā)病率隨年齡而增加,在所有年齡階段女性發(fā)病率均較男性高,預(yù)計(jì)在美國(guó)有18歲以上的支擴(kuò)患者110 000例,每年醫(yī)療費(fèi)用約6.3億美元[5]。
引用本文: 林勇. 吸入激素在支氣管擴(kuò)張癥中的應(yīng)用. 中國(guó)呼吸與危重監(jiān)護(hù)雜志, 2007, 6(3): 168-170. doi: 復(fù)制
1. | Cohen M,Sahn SA. Bronchiectasis in systemic diseases. Chest,1999;116:1063-1074. |
2. | Wilson CB,Jones PW,O’Leary CJ,et al. Validation of the St. George’s Respiratory Questionnaire in bronchiectasis.Am J Respir Crit Care Med,1997;156:536-41. |
3. | Martinez-Garcia MA,Perpina-Tordera M, Roman-Sanchez P, et al. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest,2005,128:739-745. |
4. | Ellis DA,Thornley PE,Wightman AJ,et al. Present outlook in bronchiectasis: clinical and social study and review of factors influencing prognosis.Thorax. 1981 Sep;36(9):659-64. |
5. | Trow TK. Clinical year in review II: occupational lung disease, pulmonary vascular disease, bronchiectasis, and chronic obstructive pulmonary disease.Proc Am Thorac Soc. 2006 Sep;3(7):557-60. |
6. | Tsang KW,Chan K,Ho P,et al.Sputum elastase in steady-state bronchiectasis.Chest 2000;117:420-6. |
7. | Cole PJ. Inflammation: a two-edged sword--the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147(Suppl):6-15. |
8. | Barker AF.Bronchiectasis.N Engl J Med 2002;346:1383-93. |
9. | Ho PL,Chan KN,Ip MS,et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis..Chest 1998;114:1594-8. |
10. | Silva L,Jones JAH.,Cole PJ.,et al. The immunological component of the cellular inflammatory infiltrate in bronchiectasis.Thorax 1989.44:668-73. |
11. | Gaga M,Bentley AM,Humbert M,et al.Increase in CD4+ T lymphocytes,macrophages,neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis.Thorax 1998;53:685-91. |
12. | Watt AP,Brown V,Courtney J,et al.Neutrophil apoptosis,proinflammatory mediators and cell counts in bronchiectasis.Thorax 2004;59:231-6. |
13. | Richman-Eisenstat JB, Jorens PG, Hebert CA,et al. Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases.Am J Physiol 1993;264:413-8. |
14. | Ho JC,Tipoe G,Zheng L,et al. In vitro study of regulation of IL-6 production in bronchiectasis.Respir Med. 2004 Apr;98(4):334-41. |
15. | Amitani R, Wilson R, Rutman A,.et al. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium.Am J Respir Cell Mol Biol. 1991 Jan;4(1):26-32. |
16. | King PT,Hutchinson P,Holmes PW,et al. Assessing immune function in adult bronchiectasis. Clin Exp Immunol. 2006 Jun;144(3):440-446. |
17. | Elborn JS, Johnston B, Allen F,et al. Inhaled steroids in patients with bronchiectasis.Respir Med. 1992 Mar;86(2):121-4. |
18. | Tsang KW, Ho PL, Lam WK,.et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis.Am J Respir Crit Care Med. 1998 Sep;158(3):723-7. |
19. | Tsang KW, Tan KC, Ho PL, ,et al:Exhaled nitric oxide in bronchiectasis: the effects of inhaled corticosteroid therapy,Int J Tuberc Lung Dis. 2004 Nov;8(11):1301-7. |
20. | Tsang KW,Tan KC,Ho PL,et al. Inhaled fluticasone in bronchiectasis: a 12 month study.Thorax. 2005 Mar;60(3):239-43. |
21. | Chan SL, Chan-Yeung MM, Ooi GC, et al. Validation of the Hong Kong Chinese version of the St. George Respiratory Questionnaire in patients with bronchiectasis.Chest. 2002 Dec;122(6):2030-7. |
22. | Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, Soler-Cataluna JJ.,et al.Inhaled steroids improve quality of life in patients with steady-state bronchiectasis.Respir Med. 2006 Sep;100(9):1623-32. Epub 2006 Jan 24. |
23. | Lundgren JD, Shelhamer JH.. Pathogenesis of airway mucus hypersecretion.J Allergy Clin Immunol. 1990 Feb;85(2):399-417. |
24. | Kharitonov SA, Wells AU, O’Connor BJ,et al. Elevated levels of exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care Med. 1995 Jun;151(6):1889-93. |
25. | Byrnes CA, Dinarevic S, Shinebourne EA.,et al. Exhaled nitric oxide measurements in normal and asthmatic children.Pediatr Pulmonol. 1997 Nov;24(5):312-8. |
26. | Baraldi E, Azzolin NM, Zanconato S, et al. Corticosteroids decrease exhaled nitric oxide in children with acute asthma. J Pediatr. 1997 Sep;131(3):381-5. |
27. | Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med. 1996 Jan;153(1):454-7.. |
28. | Tsang KW, Lam SK, Lam WK,et al. High seroprevalence of Helicobacter pylori in active bronchiectasis.Am J Respir Crit Care Med. 1998 Oct;158(4):1047-51. |
- 1. Cohen M,Sahn SA. Bronchiectasis in systemic diseases. Chest,1999;116:1063-1074.
- 2. Wilson CB,Jones PW,O’Leary CJ,et al. Validation of the St. George’s Respiratory Questionnaire in bronchiectasis.Am J Respir Crit Care Med,1997;156:536-41.
- 3. Martinez-Garcia MA,Perpina-Tordera M, Roman-Sanchez P, et al. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest,2005,128:739-745.
- 4. Ellis DA,Thornley PE,Wightman AJ,et al. Present outlook in bronchiectasis: clinical and social study and review of factors influencing prognosis.Thorax. 1981 Sep;36(9):659-64.
- 5. Trow TK. Clinical year in review II: occupational lung disease, pulmonary vascular disease, bronchiectasis, and chronic obstructive pulmonary disease.Proc Am Thorac Soc. 2006 Sep;3(7):557-60.
- 6. Tsang KW,Chan K,Ho P,et al.Sputum elastase in steady-state bronchiectasis.Chest 2000;117:420-6.
- 7. Cole PJ. Inflammation: a two-edged sword--the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147(Suppl):6-15.
- 8. Barker AF.Bronchiectasis.N Engl J Med 2002;346:1383-93.
- 9. Ho PL,Chan KN,Ip MS,et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis..Chest 1998;114:1594-8.
- 10. Silva L,Jones JAH.,Cole PJ.,et al. The immunological component of the cellular inflammatory infiltrate in bronchiectasis.Thorax 1989.44:668-73.
- 11. Gaga M,Bentley AM,Humbert M,et al.Increase in CD4+ T lymphocytes,macrophages,neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis.Thorax 1998;53:685-91.
- 12. Watt AP,Brown V,Courtney J,et al.Neutrophil apoptosis,proinflammatory mediators and cell counts in bronchiectasis.Thorax 2004;59:231-6.
- 13. Richman-Eisenstat JB, Jorens PG, Hebert CA,et al. Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases.Am J Physiol 1993;264:413-8.
- 14. Ho JC,Tipoe G,Zheng L,et al. In vitro study of regulation of IL-6 production in bronchiectasis.Respir Med. 2004 Apr;98(4):334-41.
- 15. Amitani R, Wilson R, Rutman A,.et al. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium.Am J Respir Cell Mol Biol. 1991 Jan;4(1):26-32.
- 16. King PT,Hutchinson P,Holmes PW,et al. Assessing immune function in adult bronchiectasis. Clin Exp Immunol. 2006 Jun;144(3):440-446.
- 17. Elborn JS, Johnston B, Allen F,et al. Inhaled steroids in patients with bronchiectasis.Respir Med. 1992 Mar;86(2):121-4.
- 18. Tsang KW, Ho PL, Lam WK,.et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis.Am J Respir Crit Care Med. 1998 Sep;158(3):723-7.
- 19. Tsang KW, Tan KC, Ho PL, ,et al:Exhaled nitric oxide in bronchiectasis: the effects of inhaled corticosteroid therapy,Int J Tuberc Lung Dis. 2004 Nov;8(11):1301-7.
- 20. Tsang KW,Tan KC,Ho PL,et al. Inhaled fluticasone in bronchiectasis: a 12 month study.Thorax. 2005 Mar;60(3):239-43.
- 21. Chan SL, Chan-Yeung MM, Ooi GC, et al. Validation of the Hong Kong Chinese version of the St. George Respiratory Questionnaire in patients with bronchiectasis.Chest. 2002 Dec;122(6):2030-7.
- 22. Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, Soler-Cataluna JJ.,et al.Inhaled steroids improve quality of life in patients with steady-state bronchiectasis.Respir Med. 2006 Sep;100(9):1623-32. Epub 2006 Jan 24.
- 23. Lundgren JD, Shelhamer JH.. Pathogenesis of airway mucus hypersecretion.J Allergy Clin Immunol. 1990 Feb;85(2):399-417.
- 24. Kharitonov SA, Wells AU, O’Connor BJ,et al. Elevated levels of exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care Med. 1995 Jun;151(6):1889-93.
- 25. Byrnes CA, Dinarevic S, Shinebourne EA.,et al. Exhaled nitric oxide measurements in normal and asthmatic children.Pediatr Pulmonol. 1997 Nov;24(5):312-8.
- 26. Baraldi E, Azzolin NM, Zanconato S, et al. Corticosteroids decrease exhaled nitric oxide in children with acute asthma. J Pediatr. 1997 Sep;131(3):381-5.
- 27. Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med. 1996 Jan;153(1):454-7..
- 28. Tsang KW, Lam SK, Lam WK,et al. High seroprevalence of Helicobacter pylori in active bronchiectasis.Am J Respir Crit Care Med. 1998 Oct;158(4):1047-51.